Cargando…
Protein regulator of cytokinesis 1: a potential oncogenic driver
Protein regulator of cytokinesis 1 (PRC1) is involved in cytokinesis. Growing evidence suggests the association of PRC1 with multiple cancers. Here, we unveil that, in 28 cancer types, PRC1 is higher expressed in tumor tissues than in non-malignant tissues. Overexpression of PRC1 indicates unfavorab...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413716/ https://www.ncbi.nlm.nih.gov/pubmed/37563591 http://dx.doi.org/10.1186/s12943-023-01802-1 |
_version_ | 1785087194534248448 |
---|---|
author | Li, Sijing Motiño, Omar Lambertucci, Flavia Martins, Isabelle Sun, Li Kroemer, Guido |
author_facet | Li, Sijing Motiño, Omar Lambertucci, Flavia Martins, Isabelle Sun, Li Kroemer, Guido |
author_sort | Li, Sijing |
collection | PubMed |
description | Protein regulator of cytokinesis 1 (PRC1) is involved in cytokinesis. Growing evidence suggests the association of PRC1 with multiple cancers. Here, we unveil that, in 28 cancer types, PRC1 is higher expressed in tumor tissues than in non-malignant tissues. Overexpression of PRC1 indicates unfavorable prognostic value, especially in ACC, LGG, KIRP, LICH, LUAD, MESO, PAAD, SARC and UCEC, while methylation of the PRC1 gene at sites associated with its inactivation has a favorable prognostic value in ACC, KIRP, LUAD, MESO, KIRP and LGG. Differentially expressed genes (DEGs) associated with high (> median) PRC1 expression contribute to key signaling pathways related with cell cycle, DNA damage and repair, EMT, cell migration, invasion and cell proliferation in most cancer types. More specifically, the DEGs involved in RAS/RAF/MAPK, PI3K/AKT, WNT, NOTCH, TGF-β, integrin, EMT process, focal adhesion, RHO GTPase-related pathway or microtubule cytoskeleton regulation are upregulated when PRC1 expression is above median, as confirmed for most cancers. Most importantly, high expression of PRC1 appears to be associated with an overabundance of poor-prognosis TH2 cells. Furthermore, positive correlations of PRC1 and some immune checkpoint genes (CD274, CTLA4, HAVCR2, LAG3, PDCD1, PDCD1LG2, TIGIT, and CD86) were observed in several cancers, especially BLCA, BRCA, KIRC, LUAD, LIHC, PRAD and THCA. These findings plead in favor of further studies validating the diagnostic and prognostic impact of PRC1 as well as the elaboration of pharmacological strategies for targeting PRC1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-023-01802-1. |
format | Online Article Text |
id | pubmed-10413716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104137162023-08-11 Protein regulator of cytokinesis 1: a potential oncogenic driver Li, Sijing Motiño, Omar Lambertucci, Flavia Martins, Isabelle Sun, Li Kroemer, Guido Mol Cancer Correspondence Protein regulator of cytokinesis 1 (PRC1) is involved in cytokinesis. Growing evidence suggests the association of PRC1 with multiple cancers. Here, we unveil that, in 28 cancer types, PRC1 is higher expressed in tumor tissues than in non-malignant tissues. Overexpression of PRC1 indicates unfavorable prognostic value, especially in ACC, LGG, KIRP, LICH, LUAD, MESO, PAAD, SARC and UCEC, while methylation of the PRC1 gene at sites associated with its inactivation has a favorable prognostic value in ACC, KIRP, LUAD, MESO, KIRP and LGG. Differentially expressed genes (DEGs) associated with high (> median) PRC1 expression contribute to key signaling pathways related with cell cycle, DNA damage and repair, EMT, cell migration, invasion and cell proliferation in most cancer types. More specifically, the DEGs involved in RAS/RAF/MAPK, PI3K/AKT, WNT, NOTCH, TGF-β, integrin, EMT process, focal adhesion, RHO GTPase-related pathway or microtubule cytoskeleton regulation are upregulated when PRC1 expression is above median, as confirmed for most cancers. Most importantly, high expression of PRC1 appears to be associated with an overabundance of poor-prognosis TH2 cells. Furthermore, positive correlations of PRC1 and some immune checkpoint genes (CD274, CTLA4, HAVCR2, LAG3, PDCD1, PDCD1LG2, TIGIT, and CD86) were observed in several cancers, especially BLCA, BRCA, KIRC, LUAD, LIHC, PRAD and THCA. These findings plead in favor of further studies validating the diagnostic and prognostic impact of PRC1 as well as the elaboration of pharmacological strategies for targeting PRC1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-023-01802-1. BioMed Central 2023-08-10 /pmc/articles/PMC10413716/ /pubmed/37563591 http://dx.doi.org/10.1186/s12943-023-01802-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Correspondence Li, Sijing Motiño, Omar Lambertucci, Flavia Martins, Isabelle Sun, Li Kroemer, Guido Protein regulator of cytokinesis 1: a potential oncogenic driver |
title | Protein regulator of cytokinesis 1: a potential oncogenic driver |
title_full | Protein regulator of cytokinesis 1: a potential oncogenic driver |
title_fullStr | Protein regulator of cytokinesis 1: a potential oncogenic driver |
title_full_unstemmed | Protein regulator of cytokinesis 1: a potential oncogenic driver |
title_short | Protein regulator of cytokinesis 1: a potential oncogenic driver |
title_sort | protein regulator of cytokinesis 1: a potential oncogenic driver |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413716/ https://www.ncbi.nlm.nih.gov/pubmed/37563591 http://dx.doi.org/10.1186/s12943-023-01802-1 |
work_keys_str_mv | AT lisijing proteinregulatorofcytokinesis1apotentialoncogenicdriver AT motinoomar proteinregulatorofcytokinesis1apotentialoncogenicdriver AT lambertucciflavia proteinregulatorofcytokinesis1apotentialoncogenicdriver AT martinsisabelle proteinregulatorofcytokinesis1apotentialoncogenicdriver AT sunli proteinregulatorofcytokinesis1apotentialoncogenicdriver AT kroemerguido proteinregulatorofcytokinesis1apotentialoncogenicdriver |